IKE Capital’s Biogen BIIB Stock Holding History

IKE Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$562K	Buy	+3,194	New	+$522K	0.49%	53

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IKE Capital's BIIB Position: Q4 2025 in Review

IKE Capital opened a new position in Biogen (BIIB) in Q4 2025: 3,194 shares worth $562K. The stake represents 0.49% of the portfolio and ranks #53 among its holdings.

1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

IKE Capital held 3,194 shares of Biogen worth $562K as of Q4 2025.
Biogen was a new IKE Capital position in Q4 2025.
Biogen made up 0.49% of IKE Capital's portfolio in Q4 2025, its #53 holding.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on IKE Capital's 13F filing for Q4 2025, filed 19 Aug 2026.